All In Biotech

Drug Trial Radar · NCT05374525

A Study Evaluating Implementation Strategies for the Delivery of Cabotegravir in Low and High-Volume PrEP Site in the United States

A Phase 4, Randomized, Open-label, Two-arm Study Evaluating Implementation Strategies for the Delivery of Cabotegravir in Low and High-volume Pre-exposure Prophylaxis (PrEP) Sites in the U.S. for HIV Uninfected MSM and Transgender Men ≥ 18

Last checked: Nov 20, 2026Latest source record: Dec 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 287 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

287

Actual

Start

May 18, 2022

Primary completion

Aug 8, 2024

Study completion Aug 8, 2024

Sponsor

Lead sponsor
ViiV HealthcareGSK (GSK)
Sponsor type
Industry
First posted
May 16, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a two-arm study evaluating the impact of two implementation strategy conditions, dynamic implementation and routine implementation on the feasibility of delivering of Cabotegravir PrEP in low and high-volume PrEP sites in the United States for men who have sex with men (MSM) and Transgender men ≥ 18 years of age. There are two types of participants in the study. Patient Study Participants (PSPs) will refer to individuals who are enrolled in the study and who will receive commercially available Cabotegravir PrEP via prescription from the PrEP provider at the corresponding site. Staff Study Participants (SSPs) will refer to site staff who are involved in administrative and clinical aspects of offering and administering PrEP to PSPs and will participate in the staff study assessments. PSPs who choose to opt for 1-month oral lead-in (OLI) will receive cabotegravir tablets for PrEP at Month 1 followed by APPRETUDE intramuscular (IM) injections on Month 2, 3 and every two months thereafter up to Month 13. PSPs who opt for Direct to injections (DTI) will receive APPRETUDE IM injections on Month 1, 2 and every two months thereafter up to Month 12. Month 6/7 refers to Month 6 (DTI)/ Month 7 (OLI). Month 12/13 refers to Month 12 (DTI)/ Month 13 (OLI).

Conditions

  • HIV Infections

Interventions

  • APRETUDEDrug

    Available as intramuscular injection.

  • Cabotegravir OLIDrug

    Available as marketed orally administered tablets.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Feasibility of Intervention Measure (FIM) Score Assessed for SSPsTime frame: At Month 12

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    San Francisco, California

  • GSK Investigational Site

    Washington D.C., District of Columbia

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Orlando, Florida

  • GSK Investigational Site

    Pensacola, Florida

  • GSK Investigational Site

    Sarasota, Florida

  • GSK Investigational Site

    Bridgeport, Kansas

  • GSK Investigational Site

    Boston, Massachusetts

  • GSK Investigational Site

    Columbia, Missouri

  • GSK Investigational Site

    St Louis, Missouri

  • GSK Investigational Site

    Rochester, New York

  • GSK Investigational Site

    The Bronx, New York

  • GSK Investigational Site

    Philadelphia, Pennsylvania

  • GSK Investigational Site

    Charleston, South Carolina

  • GSK Investigational Site

    Harlingen, Texas

  • GSK Investigational Site

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.